Vanda’s BLA for GPP Therapy Hits FDA Review with Dec. 12, 2026 Deadline
Vanda Pharmaceuticals announced FDA acceptance of its Biologics License Application for imsidolimab to treat Generalized Pustular Psoriasis with a target action date of December 12, 2026. In GEMINI-1 and GEMINI-2 trials, a single dose achieved clear or almost clear skin in 53% of patients at week 4 versus 13% on placebo, with maintained efficacy and no flares over two years.
1. FDA Acceptance and Timeline
The FDA has accepted Vanda’s Biologics License Application for imsidolimab to treat Generalized Pustular Psoriasis, setting a target action date of December 12, 2026. This acceptance launches the regulatory review phase and positions imsidolimab as a potential third Vanda product approval within 12 months.
2. Clinical Efficacy and Safety Data
In pivotal GEMINI-1 and GEMINI-2 studies, a single intravenous dose of imsidolimab produced clear or almost clear skin (GPPPGA 0/1) in 53% of patients at week 4 compared with 13% on placebo. Efficacy was sustained with monthly dosing over two years, and no flares occurred in the active arm, alongside a favorable safety profile and low anti-drug antibody incidence.
3. Market Opportunity and Pipeline Impact
Generalized Pustular Psoriasis is a rare, life-threatening disorder affecting 2 to 124 per million globally, representing a significant unmet need. If approved, imsidolimab could leverage Vanda’s existing commercial infrastructure and join NEREUS™ and BYSANTI™ as the company’s third new drug, enhancing revenue potential in orphan inflammatory indications.